Eva Thomas

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine

Edith A. Perez, Guillermo Lerzo, Xavier Pivot et al. · Journal of Clinical Oncology · 2007 · 393 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

Eva Thomas, Josep Tabernero, Monica Fornier et al. · Journal of Clinical Oncology · 2007 · 290 citations · Full text

Medicine, Oncology, Pharmacology +15

Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

W. Fraser Symmans, Mark Ayers, Edwin Clark et al. · Cancer · 2003 · 176 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

Aman U. Buzdar, S. Eva Singletary, Vicente Valero et al. · PubMed · 2002 · 162 citations

Medicine, Oncology, Pharmacology +17